Global Patient-derived Xenograft (PDX) Models Competitive Landscape Professional Research Report 2025

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $3,500	170 Pages	DIResearch	January, 2025	DIR19630387

Best Price Guarantee
Price	from $3,500
Length	170 Pages
Publisher	DIResearch
Published Date	January, 2025
SKU	DIR19630387

Research Summary

Patient-derived xenograft (PDX) models are a type of preclinical research tool used in oncology and cancer research. These models involve transplanting tumor tissues or cells directly from cancer patients into immunodeficient mice or other animal models. PDX models aim to mimic the specific characteristics and behavior of a patient＇s tumor, allowing researchers to study its growth, response to treatments, and underlying biology in a controlled laboratory setting. PDX models are valuable for drug development and personalized medicine approaches, as they can help identify and test potential therapies and assess how an individual patient＇s cancer may respond to different treatments. These models bridge the gap between in vitro cell culture studies and human clinical trials, enabling researchers to make more informed decisions about treatment strategies and drug development based on a tumor＇s real-world behavior.

According to DIResearch's in-depth investigation and research, the global Patient-derived Xenograft (PDX) Models market size was valued at XX Million USD in 2024 and is projected to reach XX Million USD by 2032, with a CAGR of XX% (2025-2032). Notably, the China market has changed rapidly in the past few years. By 2024, China's market size is expected to be XX Million USD, representing approximately XX% of the global market share. By 2032, it is anticipated to grow further to XX Million USD, contributing XX% to the worldwide market share.

The major global manufacturers of Patient-derived Xenograft (PDX) Models include Crown Bioscience, Champions Oncology, Wuxi Apptec, The Jackson Laboratory, EPO Berlin-Buch, Oncodesign, Xentech, Envigo, Charles River Laboratories, Pharmatest Services, Urosphere, MEDICILON, Horizon Discovery, Shanghai Model Organisms Center, GemPharmatech, LIDE Biotech etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.

This report studies the market size, price trends and future development prospects of Patient-derived Xenograft (PDX) Models. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Patient-derived Xenograft (PDX) Models market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Patient-derived Xenograft (PDX) Models market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Patient-derived Xenograft (PDX) Models industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Patient-derived Xenograft (PDX) Models Include:

Crown Bioscience

Champions Oncology

Wuxi Apptec

The Jackson Laboratory

EPO Berlin-Buch

Oncodesign

Xentech

Envigo

Charles River Laboratories

Pharmatest Services

Urosphere

MEDICILON

Horizon Discovery

Shanghai Model Organisms Center

GemPharmatech

LIDE Biotech

Patient-derived Xenograft (PDX) Models Product Segment Include:

Mouse Model

Rat Model

Patient-derived Xenograft (PDX) Models Product Application Include:

Preclinical Drug development

Biomarker Analysis

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Patient-derived Xenograft (PDX) Models Industry PESTEL Analysis

Chapter 3: Global Patient-derived Xenograft (PDX) Models Industry Porter’s Five Forces Analysis

Chapter 4: Global Patient-derived Xenograft (PDX) Models Major Regional Market Size and Forecast Analysis

Chapter 5: Global Patient-derived Xenograft (PDX) Models Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Passenger Patient-derived Xenograft (PDX) Models Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Patient-derived Xenograft (PDX) Models Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Patient-derived Xenograft (PDX) Models Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Patient-derived Xenograft (PDX) Models Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Patient-derived Xenograft (PDX) Models Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Patient-derived Xenograft (PDX) Models Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Patient-derived Xenograft (PDX) Models Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources

1 Patient-derived Xenograft (PDX) Models Market Overview: 1.1 Product Definition and Statistica Sclope; 1.2 Patient-derived Xenograft (PDX) Models Product by Type; 1.2.1 Mouse Model; 1.2.2 Rat Model; 1.3 Patient-derived Xenograft (PDX) Models Product by Application; 1.3.1 Preclinical Drug development; 1.3.2 Biomarker Analysis; 1.4 Global Patient-derived Xenograft (PDX) Models Market Size Analysis (2020-2032); 1.5 Patient-derived Xenograft (PDX) Models Market Development Status and Trends; 1.5.1 Patient-derived Xenograft (PDX) Models Industry Development Status Analysis; 1.5.2 Patient-derived Xenograft (PDX) Models Industry Development Trends Analysis
2 Patient-derived Xenograft (PDX) Models Market PESTEL Analysis: 2.1 Political Factors Analysis; 2.2 Economic Factors Analysis; 2.3 Social Factors Analysis; 2.4 Technological Factors Analysis; 2.5 Environmental Factors Analysis; 2.6 Legal Factors Analysis
3 Patient-derived Xenograft (PDX) Models Market Porter's Five Forces Analysis: 3.1 Competitive Rivalry; 3.2 Threat of New Entrants; 3.3 Bargaining Power of Suppliers; 3.4 Bargaining Power of Buyers; 3.5 Threat of Substitutes
4 Global Patient-derived Xenograft (PDX) Models Market Analysis by Regions: 4.1 Global Patient-derived Xenograft (PDX) Models Overall Market: 2024 VS 2025 VS 2032; 4.2 Global Patient-derived Xenograft (PDX) Models Revenue and Forecast Analysis (2020-2032); 4.2.1 Global Patient-derived Xenograft (PDX) Models Revenue and Market Share by Region (2020-2025); 4.2.2 Global Patient-derived Xenograft (PDX) Models Revenue and Market Share Forecast by Region (2026-2032)
5 Global Patient-derived Xenograft (PDX) Models Market Size by Type and Application: 5.1 Global Patient-derived Xenograft (PDX) Models Market Size by Type (2020-2032); 5.2 Global Patient-derived Xenograft (PDX) Models Market Size by Application (2020-2032)
6 North America: 6.1 North America Patient-derived Xenograft (PDX) Models Market Size and Growth Rate Analysis (2020-2032); 6.2 North America Key Manufacturers Analysis; 6.3 North America Patient-derived Xenograft (PDX) Models Market Size by Type; 6.4 North America Patient-derived Xenograft (PDX) Models Market Size by Application; 6.5 North America Patient-derived Xenograft (PDX) Models Market Size by Country; 6.5.1 US; 6.5.2 Canada
7 Europe: 7.1 Europe Patient-derived Xenograft (PDX) Models Market Size and Growth Rate Analysis (2020-2032); 7.2 Europe Key Manufacturers Analysis; 7.3 Europe Patient-derived Xenograft (PDX) Models Market Size by Type; 7.4 Europe Patient-derived Xenograft (PDX) Models Market Size by Application; 7.5 Europe Patient-derived Xenograft (PDX) Models Market Size by Country; 7.5.1 Germany; 7.5.2 France; 7.5.3 United Kingdom; 7.5.4 Italy; 7.5.5 Spain; 7.5.6 Benelux
8 China: 8.1 China Patient-derived Xenograft (PDX) Models Market Size and Growth Rate Analysis (2020-2032); 8.2 China Key Manufacturers Analysis; 8.3 China Patient-derived Xenograft (PDX) Models Market Size by Type; 8.4 China Patient-derived Xenograft (PDX) Models Market Size by Application
9 APAC (excl. China): 9.1 APAC (excl. China) Patient-derived Xenograft (PDX) Models Market Size and Growth Rate Analysis (2020-2032); 9.2 APAC (excl. China) Key Manufacturers Analysis; 9.3 APAC (excl. China) Patient-derived Xenograft (PDX) Models Market Size by Type; 9.4 APAC (excl. China) Patient-derived Xenograft (PDX) Models Market Size by Application; 9.5 APAC (excl. China) Patient-derived Xenograft (PDX) Models Market Size by Country; 9.5.1 Japan; 9.5.2 South Korea; 9.5.3 India; 9.5.4 Australia; 9.5.5 Southeast Asia
10 Latin America: 10.1 Latin America Patient-derived Xenograft (PDX) Models Market Size and Growth Rate Analysis (2020-2032); 10.2 Latin America Key Manufacturers Analysis; 10.3 Latin America Patient-derived Xenograft (PDX) Models Market Size by Type; 10.4 Latin America Patient-derived Xenograft (PDX) Models Market Size by Application; 10.5 Latin America Patient-derived Xenograft (PDX) Models Market Size by Country; 10.5.1 Mexico; 10.5.2 Brazil
11 Middle East & Africa: 11.1 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size and Growth Rate Analysis (2020-2032); 11.2 Middle East & Africa Key Manufacturers Analysis; 11.3 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size by Type; 11.4 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size by Application; 11.5 Middle East & Africa Patient-derived Xenograft (PDX) Models Market Size by Country; 11.5.1 Saudi Arabia; 11.5.2 South Africa
12 Competition by Manufacturers: 12.1 Global Patient-derived Xenograft (PDX) Models Market Revenue by Key Manufacturers (2021-2025); 12.2 Patient-derived Xenograft (PDX) Models Competitive Landscape Analysis and Market Dynamic; 12.2.1 Patient-derived Xenograft (PDX) Models Competitive Landscape Analysis; 12.2.2 Global Key Manufacturers Headquarter Location and Key Area Sales; 12.2.3 Market Dynamic
13 Key Companies Analysis: 13.1 Crown Bioscience; 13.1.1 Crown Bioscience Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.1.2 Crown Bioscience Patient-derived Xenograft (PDX) Models Product Portfolio; 13.1.3 Crown Bioscience Patient-derived Xenograft (PDX) Models Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.2 Champions Oncology; 13.2.1 Champions Oncology Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.2.2 Champions Oncology Patient-derived Xenograft (PDX) Models Product Portfolio; 13.2.3 Champions Oncology Patient-derived Xenograft (PDX) Models Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.3 Wuxi Apptec; 13.3.1 Wuxi Apptec Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.3.2 Wuxi Apptec Patient-derived Xenograft (PDX) Models Product Portfolio; 13.3.3 Wuxi Apptec Patient-derived Xenograft (PDX) Models Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.4 The Jackson Laboratory; 13.4.1 The Jackson Laboratory Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.4.2 The Jackson Laboratory Patient-derived Xenograft (PDX) Models Product Portfolio; 13.4.3 The Jackson Laboratory Patient-derived Xenograft (PDX) Models Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.5 EPO Berlin-Buch; 13.5.1 EPO Berlin-Buch Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.5.2 EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Product Portfolio; 13.5.3 EPO Berlin-Buch Patient-derived Xenograft (PDX) Models Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.6 Oncodesign; 13.6.1 Oncodesign Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.6.2 Oncodesign Patient-derived Xenograft (PDX) Models Product Portfolio; 13.6.3 Oncodesign Patient-derived Xenograft (PDX) Models Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.7 Xentech; 13.7.1 Xentech Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.7.2 Xentech Patient-derived Xenograft (PDX) Models Product Portfolio; 13.7.3 Xentech Patient-derived Xenograft (PDX) Models Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.8 Envigo; 13.8.1 Envigo Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.8.2 Envigo Patient-derived Xenograft (PDX) Models Product Portfolio; 13.8.3 Envigo Patient-derived Xenograft (PDX) Models Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.9 Charles River Laboratories; 13.9.1 Charles River Laboratories Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.9.2 Charles River Laboratories Patient-derived Xenograft (PDX) Models Product Portfolio; 13.9.3 Charles River Laboratories Patient-derived Xenograft (PDX) Models Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.10 Pharmatest Services; 13.10.1 Pharmatest Services Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.10.2 Pharmatest Services Patient-derived Xenograft (PDX) Models Product Portfolio; 13.10.3 Pharmatest Services Patient-derived Xenograft (PDX) Models Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.11 Urosphere; 13.11.1 Urosphere Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.11.2 Urosphere Patient-derived Xenograft (PDX) Models Product Portfolio; 13.11.3 Urosphere Patient-derived Xenograft (PDX) Models Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.12 MEDICILON; 13.12.1 MEDICILON Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.12.2 MEDICILON Patient-derived Xenograft (PDX) Models Product Portfolio; 13.12.3 MEDICILON Patient-derived Xenograft (PDX) Models Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.13 Horizon Discovery; 13.13.1 Horizon Discovery Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.13.2 Horizon Discovery Patient-derived Xenograft (PDX) Models Product Portfolio; 13.13.3 Horizon Discovery Patient-derived Xenograft (PDX) Models Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.14 Shanghai Model Organisms Center; 13.14.1 Shanghai Model Organisms Center Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.14.2 Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Product Portfolio; 13.14.3 Shanghai Model Organisms Center Patient-derived Xenograft (PDX) Models Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.15 GemPharmatech; 13.15.1 GemPharmatech Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.15.2 GemPharmatech Patient-derived Xenograft (PDX) Models Product Portfolio; 13.15.3 GemPharmatech Patient-derived Xenograft (PDX) Models Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025); 13.16 LIDE Biotech; 13.16.1 LIDE Biotech Basic Company Profile (Employees, Areas Service, Competitors and Contact Information); 13.16.2 LIDE Biotech Patient-derived Xenograft (PDX) Models Product Portfolio; 13.16.3 LIDE Biotech Patient-derived Xenograft (PDX) Models Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
14 Industry Chain Analysis: 14.1 Patient-derived Xenograft (PDX) Models Industry Chain Analysis; 14.2 Patient-derived Xenograft (PDX) Models Industry Raw Material and Suppliers Analysis; 14.2.1 Patient-derived Xenograft (PDX) Models Key Raw Material Supply Analysis; 14.2.2 Raw Material Suppliers and Contact Information; 14.3 Patient-derived Xenograft (PDX) Models Typical Downstream Customers; 14.4 Patient-derived Xenograft (PDX) Models Sales Channel Analysis
15 Research Findings and Conclusion
16 Methodology and Data Source: 16.1 Methodology/Research Approach; 16.2 Research Scope; 16.3 Benchmarks and Assumptions; 16.4 Date Source; 16.4.1 Primary Sources; 16.4.2 Secondary Sources; 16.5 Data Cross Validation; 16.6 Disclaimer